© 2007 American Thoracic Society
SERPINE2 and COPDTo the Editor:The article on SERPINE2 by Zhu and colleagues (1) provides convincing observations regarding the implication of the SERPINE2 gene in chronic obstructive pulmonary disease (COPD), but the information provided regarding the two "populations" they studied is scanty, even in the online supplement. The first dataset is composed of middle-aged probands and siblings with COPD from various geographic locations through a network of at least six countries; the mode of ascertainment and phenotypic description do not seem to have been reported until now. The other dataset is a case-control population from Bergen, Norway, an already well-studied population regarding the epidemiology of COPD. Although the authors used genomic controls to address potential population stratification, it would be of interest to provide the geographic distribution of the families studied, including a table with lung function and smoking. Is there any overlap with populations already described in the literature? Were probands recruited in hospitals, in the general population, or in a combination of these? How many of their siblings were contacted and participated? More descriptive information regarding ICGN subjects (such as lung function and smoking according to gender) would be useful to interpret the results. The authors stated that the center from which the patients came was adjusted for in the PBAT analysis. Were results consistent across countries of ascertainment? Providing these answers would strengthen the conclusions of the paper. Further, it would be interesting to know in relation to the known sex-specific dysanapsis whether results regarding FEV1/FVC were similar in men and women.
INSERM, U780, Epidemiology and Biostatistics, Villejuif Cedex, France FOOTNOTES
Conflict of Interest Statement: F.K. has received a research grant from Merck, Sharp & Dohme in 2002 of REFERENCES
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||